Navigation Links
University of Minnesota startup to treat challenging bacterial infection
Date:5/16/2012

A live biological preparation developed by University of Minnesota researchers could put a stop to an increasingly prevalent, and sometimes deadly, infection caused by the bacterium Clostridium difficile. CIPAC Limited, based in Australia with subsidiaries in California, will continue to work with the university to advance the technology to treat patients by using frozen and, eventually, encapsulated preparations.

C. difficile affects several million people and is linked to 14,000 deaths per year in the United States, according to the Centers for Disease Control and Prevention. Symptoms of C. difficile infection include fever, nausea, and diarrhea, and most often occur following a prescribed course of antibiotics. The antibiotics kill normal microbes that live in the colon, thereby making the patient more susceptible to infections such as C. difficile.

Paradoxically, while the cause of C. difficile infection is exposure to antibiotics, the infection itself is also treated using antibiotics, which can make things worse. C. difficile infections typically affect older adults in hospitals or in long-term care facilities, but is increasingly spreading into the wider community. In recent years it has become more frequent, more severe and more difficult to treat. Patients suffering from the infection require costly care -- researchers suggest it costs $2,500-7,000 to treat each patient suffering from C. difficile.(1)

"C. difficile can be suppressed with antibiotics, which have the unfortunate side effect of killing off the normal colon bacteria that offer protection against infection," says Alexander Khoruts, M.D., co-inventor and associate professor of medicine within the university's division of Gastroenterology, Hepatology and Nutrition.

"Antibiotics don't work very well because they only suppress the C. difficile. Once you remove the antibiotic, it produces more of the infection," says Michael Sadowsky, co-inventor and McKnight University professor in the Biotechnology Institute and department of Soil, Water, and Climate.

The invention, a bacterial preparation, can enable restoration of normal bacteria in the colon.

"We are very excited to be working with the University of Minnesota in commercializing a treatment that has approximately 95% efficacy," says Geoff Rosenhain, founder of CIPAC. "Our goal is to bring to market a safe, natural and effective alternative to current treatment options, and to restore the wellbeing of patients suffering from debilitating C. difficile infections."

CIPAC is working with the FDA to begin clinical trials for the preparation. The technology was licensed exclusively to CIPAC by the university's Office for Technology Commercialization.


'/>"/>

Contact: John Merritt
jmerritt@umn.edu
612-624-2609
University of Minnesota
Source:Eurekalert

Related medicine news :

1. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
2. University of Houston Graduate College of Social Work announces partnership with MD Anderson
3. Neuropsychologist receives University of Houstons highest faculty honor
4. Louisiana Tech University professor earns NSF Early Career Development grant
5. Rice University student engineers automate limb lengthening for kids
6. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
7. University of Cincinnati researchers win $3.7M grant from US Department of Defense
8. Oxford University Press partners with the Physical Society of Japan
9. Fewer women need repeat breast cancer surgeries with new service at University of Michigan
10. Kessler Foundation scientist addresses opening of science complex of William Paterson University
11. 90 percent of firefighters exhibit symptoms of PTSD according to Ben-Gurion University researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Park, KS (PRWEB) , ... February 08, 2016 , ... ... a leader in Mole removal products. , Moles are derived from a cluster of ... appear in all the wrong places and create a lifetime of embarrassment. Historically, ...
(Date:2/8/2016)... ... , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated personal ... birthday on February 10th. During this time, people can achieve better health, greater ... people from over 40 different countries as an “ordinary man with an extraordinary gift.” ...
(Date:2/8/2016)... ... ... According to research by the National Association of Dental ... certified or obtain continuing education. To increase patient awareness of the lack of ... to inform dentists and patients about the possible lack of skills and knowledge ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... Women's Excellence ... National Wear Red Day. National Wear Red Day is the first Friday each ... Heart disease and stroke cause 1 in 3 deaths among women each year – ...
(Date:2/7/2016)... AZ (PRWEB) , ... February 07, 2016 , ... ... Neck and Facial Plastics, has added Kybella® to his medical and surgical expertise. ... a newly approved FDA injectable medication used as a non-surgical alternative for reduction ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... India , February 8, 2016 ... a new market research report "Ablation Technologies Market by ... (Csardiovascular, Cancer, Pain Management, Cosmetic Surgery, Ophthalmology, Gynecology) - ... studies the global market over the forecast period of ... $4.44 Billion by 2020, at CAGR of 10.5% from ...
(Date:2/8/2016)... Kan. , Feb. 8, 2016 /PRNewswire/ ... organization that formerly specialized in the development ... recently announced that it has divided its ... Capital. While Nueterra Capital will continue the ... services, NueHealth will operate a national system ...
(Date:2/8/2016)... , Feb. 8, 2016  A research team ... scientists has discovered details of how the abnormal breakage ... a particularly aggressive form of acute lymphoblastic leukemia (ALL). ... which genetic mutations trigger overproduction of immature cells, called ... The discoveries of the malfunction underlying the type called ...
Breaking Medicine Technology: